| 1/28/2014 | PP | Idenix negotiates $106.73 million registered direct offering of stock
|
| 4/8/2011 | PP | Idenix prices $5 million private placement of common stock at $2.80
|
| 4/7/2011 | PP | Idenix reports it will sell $5 million of stock in a private placement
|
| 2/6/2009 | PP | New Issue: Idenix plans $17.01 million private placement of shares
|
| 2/6/2009 | PP | Market Commentary: Idenix negotiates $17.01 million deal with GlaxoSmithKline; Global Construction gets A$4.66 million
|
| 10/27/2006 | BT | Idenix ends third quarter with $210 million cash; will launch Tyzeka within one month
|
| 9/21/2006 | BT | Idenix: Telbivudine approved in Switzerland for chronic hepatitis B
|
| 7/11/2006 | BT | Market Commentary: Connetics stock regains 3%; Anadys adds 8% on new exec, moves Idenix, Vertex up, too; Xoma rises 5%
|
| 6/6/2006 | BT | Market Commentary: Xenoport deal emerges; Human Genome up 4%; Anadys, Idenix drop on HGSI news; Onyx up
|
| 5/2/2006 | BT | Idenix Pharmaceuticals reports first-quarter total revenues of $13.1 million
|
| 5/1/2006 | BT | Idenix says lower dose of valopicitabine shows comparable antiviral activity as higher dose
|
| 5/1/2006 | BT | Market Commentary: Teva shares, convertibles gain on Zocor ruling; NeoPharm off amid downsizing; Alnylam, Idenix drop
|
| 4/4/2006 | BT | Market Commentary: Valeant up on restructuring; Nabi gains; Avanir rises on drug filing; Enzon higher; ViroPharma eyed
|
| 3/29/2006 | BT | Market Commentary: Amylin shares up ahead of deal; Idenix off despite Novartis aid; Antigenics, cancer names higher
|
| 3/29/2006 | BT | Idenix licenses valopicitabine to Novartis for potential fees of up to $525 million
|
| 3/27/2006 | BT | Idenix, Novartis say telbivudine suppresses hepatitis B virus better than lamivudine
|
| 3/24/2006 | BT | Bear Stearns maintains Idenix at outperform
|
| 3/24/2006 | BT | Market Commentary: BioMarin shares, new bonds gain; Cephalon loses 13%; Idenix falls 28%; King slips; Encysive declines
|
| 3/23/2006 | BT | Idenix modifies hepatitis C treatment in phase 2b trial
|
| 3/16/2006 | BT | Idenix denies claim that it owes two universities $15.3 million in licensing fees
|
| 3/2/2006 | BT | Idenix, Novartis amend terms for license of Idenix hepatitis C drug
|
| 2/9/2006 | BT | Sareum, Idenix form agreement to discover novel hepatitis C compounds
|
| 2/7/2006 | BT | Idenix, Novartis seek European approval of telbivudine to treat chronic hepatitis B
|
| 1/9/2006 | BT | Idenix says first four weeks of phase 2b valopicitabine trial shows promise for hepatitis C patients
|
| 1/3/2006 | BT | Idenix, Novartis submit NDA for 600 mg telbivudine to treat hepatitis B
|
| 12/14/2005 | BT | Idenix: Early phase 2b data shows valopicitabine with pegylated interferon increases viral suppression in hepatitis C
|
| 11/28/2005 | BT | Galapagos, Idenix form collaboration for infectious disease programs
|
| 11/28/2005 | BT | Idenix underwriters exercise greenshoe option, raising deal to 9.35 million shares
|
| 11/14/2005 | BT | Study results on Novartis/Idenix drug Telbivudine shows significant suppression of hepatitis B virus
|
| 11/11/2005 | BT | Idenix's Valopicitabine/pegylated interferon combo suppresses hepatitis C virus, study shows
|
| 11/9/2005 | BT | Leerink Swann rates Idenix market perform
|
| 10/26/2005 | BT | New Issue: Idenix raises $150 million in upsized follow-on at $20.61, pat with close
|
| 10/26/2005 | BT | Market Commentary: NxStage talk sweetened; Predix pulls IPO; Biosite plunges; CV Therapeutics dives; Idenix rises
|
| 10/25/2005 | BT | Market Commentary: Indevus spikes on trial; Idenix off big on follow-on sale; Rigel up on Serono pact; Sepracor rises
|
| 10/24/2005 | BT | Idenix to sell 6.59 million shares, stockholders to sell 940,000
|
| 8/19/2005 | BT | Idenix Pharmaceuticals files $150 million shelf
|
